Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 25
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Quoin Pharmaceuticals Ltd
QNRX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$4.02
0.01
0.25%
Ult. Agg.: Oct 23, 6:37 PM
Get Report
Panoramica
Notizie
Previsioni utili
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Quoin Pharmaceuticals Financials
Quoin Pharmaceuticals (QNRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.61) by 18.01 percent. This is a 69.75 percent increase over losses of $(6.28) per
Benzinga Newsdesk
PRO
Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.72) by 2.91 percent. This is a 72.77 percent increase over losses of $(6.50) per share
Benzinga Newsdesk
PRO
Quoin Pharmaceuticals Q4 EPS $(1.74) Beats $(4.02) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(4.02) by 56.72 percent. This is a 85.96 percent increase over losses of $(12.39) per share
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Quoin Pharmaceuticals Q3 EPS $(6.71) Misses $(6.50) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(6.71) per share which missed the analyst consensus estimate of $(6.50) by 3.15 percent. This is a 59.21 percent increase over losses of $(16.45) per
Benzinga Newsdesk
Earnings Scheduled For November 6, 2025
Benzinga Insights
